natgillin/translations-raw huggingface dataset:
Bronchospasm, dysphonia, oropharyngeal pain, oropharyngeal spasm
bronhospazem, disfonija, orofaringealna bolečina, orofaringealni spazem
Bronchospasm, Dyspnoea
bronhospazem, dispneja
Bronchospasm, including paradoxical4
bronhospazem, vključno s paradoksnim4
bronchospasm, pharyngolaryngeal pain, rhinnorhoea, tachypnoea, upper respiratory tract congestion
bronhospazem, bolečine v požiralniku in grlu, rinoreja, tahipneja, kongestija zgornjega dela dihalnih poti
Bronchospasm, pulmonary oedema
bronhospazem, pljučni edem
Bronchospasm, Respiratory arrest
bronhospazem, respiratorni zastoj
Bronchospasm, wheezing
bronhospazem, sopenje
Bronchospasm-like symptoms
bronhospazmu podobni simptomi
bronchospasm1, chest discomfort, rhinorrhoea, haemoptysis1
bronhospazem1, bolečine v prsih, rinoreja, hemoptiza1
Bronchospasm2
tahikardija
Bronchospasm4,
bronhospazem4,
Bronchospasm; Tachypnoea; Haemoptysis; Epistaxis
Bronhospazem; tahipneja; hemoptiza; epistaksa
Brown glass bottles (Hydrolytic Class III) containing either 50 ml, 100 ml or 10 x 50 ml solution.
Rjave stekleničke (Hidrolitski razred III), ki vsebujejo po 50 ml, 100 ml ali 10 x 50 ml raztopine.
Brown glass bottles (Hydrolytic Class III) containing either 50, 100 ml or 500ml (10 x 50 ml) solution.
Rjave stekleničke (Hidrolitski razred III), ki vsebujejo po 50, 100 ml ali 500 ml (10 x 50 ml) raztopine.
Brown glass bottles (Hydrolytic Class III) containing either 50, 100 ml or 500ml (10 x 50 ml) solution.
Rjave stekleničke (Hidrolitski razred III), ki vsebujejo po 50, 100 ml ali 500ml (10 x 50 ml) raztopine.
Brown palatable oblong shaped chewable tablets with a score line.
Rjave okusne ovalne žvečljive tablete z zarezo..
Brown spots or patches on the face
rjave pege ali lise na obrazu,
Brown-yellow, convex, ovaloid tablet with a bevelled edge, with “T12” debossed on one side and “NVR” on the other.
Rjavo rumena konveksna ovalna tableta z zaobljenim robom, z oznako “T12” vtisnjeno na eni strani in oznako “NVR” na drugi.
Brownish or greyish red, oval, unscored film-coated tablets marked with ‘LCE 100’ on one side.
Rjavkaste ali sivkasto-rdeče ovalne filmsko obložene tablete brez zareze z oznako »LCE 100« na eni strani.
Brownish or greyish red, round, convex, unscored film-coated tablets marked with ‘LCE 50’ on one side.
Rjavkaste ali sivkasto-rdeče okrogle konveksne filmsko obložene tablete brez zareze z oznako »LCE 50« na eni strani.
Brownish orange, oval shaped, biconvex, film-coated tablets, debossed on one side with ‘IM’ and ‘T2’ on either side of breakline and plain on the other side.
Rjavooranžne, ovalne, bikonveksne filmsko obložene tablete z vtisnjenima oznakama “IM” in “T2” na vsaki strani zareze na eni strani tablete in brez oznake na drugi strani.
Brownish orange, round, biconvex, film-coated tablets, debossed on one side with ‘IM’ and ‘T1’ on either side of breakline and plain on the other side.
Rjavooranžne, okrogle, bikonveksne filmsko obložene tablete z vtisnjenima oznakama “IM” in “T1” na vsaki strani zareze na eni strani tablete in brez oznake na drugi strani.
bruise more easily
hitro dobite modrice
Bruises
modrice
bruises
modrice,
bruises due to a low platelet count
modrice zaradi nizkega števila trombocitov
Bruises, falls and injuries
modrice, padci in poškodbe
Bruising
Hypersensitivity
bruising
modrice,
Bruising
podplutbe
Bruising
podplutbe,
Bruising
pojavljanje podplutb
bruising (contusion);
podplutbe (kontuzija),
bruising (ecchymosis)
modrica (ekhimoza)
Bruising (haematoma and contusion)
modrice (hematomi in zmečkanine)
bruising (haematoma) where the injection is given stomach and digestion problems such as diarrhoea, vomiting and nausea.
podplutba (hematom) na mestu injiciranja želodčne in prebavne težave, npr. driska, bruhanje in slabost s siljenjem na bruhanje.
bruising (including purpura),
modrice (vključno s purpuro),
Bruising and fractures.
modrice in zlomi;
bruising and frequent infections (aplastic anaemia)
podplutbe in pogoste okužbe (aplastična anemija)
Bruising and frequent infections (aplastic anaemia)
podplutbe in pogoste okužbe (aplastična anemija),
bruising and swelling in your stomach, your bowel, into the rectum
modricami in oteklinami krvavitvami v želodcu, črevesju, danki
bruising and swelling vaginal bleeding
modricami in oteklinami
bruising at the injection site
podplutba na mestu injiciranja,
Bruising at the injection site.
Modrica na mestu injiciranja
Bruising events were more frequently reported in patients taking Jakavi compared with the reference treatments (21.3% versus 11.6%).
O podplutbah so pogosteje poročali pri bolnikih, ki so prejemali zdravilo Jakavi, v primerjavi s tistimi, ki so prejemali primerjalno zdravilo (21,3 % v primerjavi z 11,6 %).
bruising gastro-intestinal bleeding (e.g. bleeding from the stomach or bowel)
modrice, krvavitev v prebavilih (npr. krvavitev v želodcu ali črevesu).
bruising or
podplutbe ali
Bruising or bleeding at injection site, soreness or swelling at injection site, build up of fat below the surface of the skin at injection site, swelling of the extremities, weakness, fever.
podplutba ali krvavitev na mestu injiciranja, bolečina ali oteklina na mestu injiciranja, povečanje količine podkožnega maščobnega tkiva na mestu injiciranja, oteklost okončin, šibkost, vročina
Bruising or bleeding more easily than normal.
modrice ali krvavitve, do katerih pride prej kot običajno
Bruising or bleeding under the skin
modrice ali krvavitev pod kožo,
Bruising or pain at the injection site
podplutba ali bolečina na mestu injiciranja
bruising or swelling (oedema)
nastanek modric ali oteklin (edemi);
bruising or swelling of the penis and pain in the penis a small collection of blood under the skin at the injection site
modrica ali oteklina penisa in bolečina v penisu majhna količina krvi pod kožo na mestu injiciranja
Bruising was reported in similar frequencies in Jakavi and BAT arms (10.9% versus 8.1%).
O podplutbah so poročali približno enako pogosto pri bolnikih, ki so prejemali zdravilo Jakavi, in pri tistih, ki so prejemali najboljše razpoložljivo zdravljenje (10,9 % v primerjavi z 8,1 %).
Bruising, haematoma (unusual bleeding under the skin), nose bleeds, bleeding in the stomach or bowels, increased bleeding at the site of a puncture wound
odrgnine, hematomi (neobičajne krvavitve pod kožo), krvavitve iz nosu, krvavitve iz želodca ali
bruising, hair loss, changes to skin colour, increased sweating, dry skin, or other skin problems;
podplutbe, izguba las, spremembe barve kože, čezmerno potenje, suha koža ali druge težave s kožo;
Bruising, hot flush or nosebleed, warm, red skin (flushing)
podplutbe, navali vročine ali krvavitev iz nosu, topla in pordela koža (zardevanje)
Bruising, hot flush or nosebleed, warm, red skin (flushing)
podplutbe, vročinski oblivi ali krvavitev iz nosu, topla in pordela koža (zardevanje)
Bruising, hot flush or nosebleed, warm, red skin (flushing)
podplutbe, vročinski oblivi ali krvavitev iz nosu, topla in pordela koža (zardevanje),
bruising, shaking
podplutbe, tresenje,
Bruising.
modrice,
bruising;
modrice;
Brunner’s glands carcinoma occurred in the duodenum at ≥1 mg/kg/day in females and at 3 mg/kg/day in males, and mucous cell hyperplasia was evident in the glandular stomach at 3 mg/kg/day in males, which occurred at ≥0.9, 7.8 and 7.8 times the AUC in patients administered the RDD, respectively.
Karcinom Brunnerjevih žlez v dvanajstniku se je pojavil pri odmerjanju ≥ 1 mg/kg/dan pri samicah in pri 3 mg/kg/dan pri samcih, zasledili so hiperplazijo želodčne sluznice pri odmerjanju 3 mg/kg/dan pri samcih, ki se je pojavila pri ≥ 0,9-, 7,8- in 7,8-kratniku vrednosti AUC bolnikov, ki prejemajo RDD.
Brusing of the skin at the injection site, fever and nausea, generally feeling unwell and shivering.
Modrice na koţi na mestu injiciranja, zvišana telesna temperature, splošno slabo počutje in tresenje
Bruxism, Confusional state, Depressed mood, Depression, Disorientation, Early morning awakening, Flat affect, Hallucination, Impulsive behaviour, Indifference, Insomnia, Restlessness, Sleep disorder
bruksizem, konfuznost, depresivno razpoloženje, depresija, dezorientiranost, zbujanje zgodaj zjutraj, apatičnost, halucinacije, impulzivno vedenje, indiferentnost, nespečnost, nemir, motnje spanja
BSA (m2)
TP (m2)
BSA (m2) =  (Height (cm) X Weight (kg) / 3600)
telesna površina (m2) =  (višina (cm) X telesna masa (kg) / 3600)
BSA range (m2)
Razpon telesne površine (m2)
BSA Range (m2)
Telesna površina (m2)
BSA subject (m2) x 1.73
BSA bolnika (m2)
BSA- normalized clearance of bortezomib in paediatric patients was similar to that observed in adults.
Očistek bortezomiba, normaliziran na BSA, je bil pri pediatričnih bolnikih podoben očistku, ki so ga opazili pri odraslih.
BSA-normalized clearance and half-life were similar across the age range and consistent with that determined in healthy adult subjects, supporting the recommended dose of 2 mg/m2.
Vrednosti na telesno površino prilagojenega očistka in razpolovnega časa so bile pri vseh starostih podobne in konsistentne z vrednostmi pri zdravih odraslih osebah, kar podpira uporabo priporočenega odmerka 2 mg/m2.
BTDx (N=130)
BTDx ( n=130)
BTV 2 antigen ...........................................................................................................
antigen BTV 2 ...........................................................................................................
BTV 8 antigen ......................................................................................................  2.1 log10 pixels/dose
Antigen BTV8 .............................................................................................. 2,1 log10 pikslov/odmerek
BTVPUR AlSap 1 contains bluetongue virus of one types (‘serotype 1’).
Cepivo BTVPUR AlSap 1 vsebuje en tip virusa modrikastega jezika („serotip 1“).
BTVPUR AlSap 1 suspension for injection for sheep and cattle
BTVPUR AlSap 1 suspenzija za injiciranje za ovce in govedo
BTVPUR AlSap 1 suspension for injection for sheep and cattle.
BTVPUR AlSap 1 suspenzija za injiciranje za ovce in govedo
BTVPUR AlSap 1 was initially authorised under ‘exceptional circumstances’.
Cepivo BTVPUR AlSap 1 je prvotno pridobilo dovoljenje za promet v „izjemnih okoliščinah“.
BTVPUR ALSap 2-4 is a vaccine.
BTVPUR AlSap 2-4 je cepivo.
BTVPUR AlSap 2-4 suspension for injection for sheep
BTVPUR AlSap 2-4 suspenzija za injiciranje za ovce
BTVPUR AlSap 2-4 was initially authorised under ‘exceptional circumstances’.
Cepivo BTVPUR AlSap 2-4 je prvotno pridobilo dovoljenje za promet v „izjemnih okoliščinah“.
BTVPUR AlSap 2-4suspension for injection for sheep
BTVPUR AlSap 2-4 suspenzija za injiciranje za ovce
BTVPUR AlSap 8 contains bluetongue virus of one type (‘serotype 8’).
Zdravilo BTVPUR AlSap 8 vsebuje en tip virusov modrega jezika („serotip 8“).
BTVPUR AlSap 8 suspension for injection
BTVPUR AlSap 8 suspenzija za injiciranje
BTVPUR AlSap 8 was initially authorised under ‘exceptional circumstances’.
Zdravilo BTVPUR AlSap 8 je prvotno pridobilo dovoljenje za promet v „izjemnih okoliščinah“.
BTVPUR AlSap 8, suspension for injection
BTVPUR AlSap 8 suspenzija za injiciranje.
BTVPUR contains bluetongue virus of one or two types selected from serotypes 1, 4 and 8.
Zdravilo BTVPUR vsebuje eno ali dve vrsti izbranih serotipov 1, 4 in 8 virusa bolezni modrikastega jezika.
BTVPUR injection for sheep and cattle
BTVPUR suspenzija za injiciranje za ovce in govedo
BTVPUR is developed from AlSap 1-8 originally authorised under ‘exceptional circumstances’ on 17 December 2010 because limited information was available at the time of approval.
Zdravilo BTVPUR je bilo razvito iz zdravila AlSap 1–8, ki je prvotno 17. decembra 2010 pridobilo dovoljenje za promet „v izjemnih okoliščinah“, saj so bile ob odobritvi na voljo le omejene informacije.
BTVPUR suspension for injection for sheep and cattle.
BTVPUR suspenzija za injiciranje za ovce in govedo
Buccal tablet
Bukalna tableta
BUCCOLAM 10 mg oromucosal solution
BUCCOLAM 10 mg oralna raztopina
BUCCOLAM 10 mg oromucosal solution For children aged 10 years to less than 18 years
BUCCOLAM 10 mg oralna raztopina za otroke, stare od 10 let do manj kot 18 let
BUCCOLAM 5 mg oromucosal solution
BUCCOLAM 5 mg oralna raztopina
BUCCOLAM 5 mg oromucosal solution midazolam
BUCCOLAM 5 mg oralna raztopina midazolam
BUCCOLAM 7.5 mg oromucosal solution
BUCCOLAM 7,5 mg oralna raztopina
BUCCOLAM is contraindicated in patients with severe hepatic impairment (see section 4.3).
Zdravilo BUCCOLAM je kontraindicirano pri bolnikih s hudo[AP1] okvaro jeter (glejte poglavje 4.3).
Buccolam is given in the side of the child’s mouth.
Zdravilo Buccolam se daje na eno stran otrokovih ust.
BUCCOLAM may make the patient sleepy, forgetful or affect their concentration and co-ordination.
Zdravilo BUCCOLAM lahko naredi bolnika zaspanega, pozabljivega ali vpliva na njegovo koncentracijo ali koordinacijo.
Bucharest 032266 Romania
Bucharest 032266 Romunija
Buckinghamshire HP7 9NA United Kingdom
Little Chalfont Buckinghamshire HP7 9NA Velika Britanija
Buckinghamshire, MK7 7AJ UNITED KINGDOM
Buckinghamshire, MK7 7AJ Združeno kraljestvo
Bucks HP7 9NA United Kingdom
Bucks HP7 9NA Velika Britanija
Bucks HP7 9NA United Kingdom
Little Chalfont Bucks HP7 9NA Velika Britanija
Budapest H-1047
Budapest H-1047,
Budd–Chiari syndrome (the clinical symptoms caused by blockage of the hepatic veins)
Budd-Chiarijev sindrom (klinični simptomi, ki jih povzroča blokada ven v jetrih)
Budd–Chiari syndrome (the clinical symptoms caused by blockage of the hepatic veins)
Budd-Chiary sindrom (klinični simptomi, ki jih povzroča blokada ven v jetrih)
budesonide / formoterol fumarate dihydrate
budezonid/formoterolijev fumarat dihidrat
Budesonide has a high systemic clearance (approximately 1.2 L/min) and the plasma elimination half-life after i.v. dosing averages 4 hours.
Budezonid ima velik sistemski očistek (približno 1,2 l/min) njegova razpolovna doba izločanja iz plazme po i. v. uporabi pa je v povprečju 4 ure.
Budesonide has a high systemic clearance (approximately 1.2 L/min) and the plasma elimination half-life after i.v. dosing averages 4 hours.
Budezonid ima velik sistemski očistek (približno 1,2 l/min) njegova razpolovna doba izločanja iz plazme po i.v. uporabi pa je v povprečju 4 ure.
budesonide, inhaled/nasal fluticasone, dexamethasone if taken by mouth or through injection
budezonid, flutikazon, ki ga vdihnete skozi usta ali nos, deksametazon, ki ga zaužijete skozi usta ali ga prejemate z injekcijo
budesonide/ formoterol fumarate dihydrate
budezonid/formoterolijev fumarat dihidrat
budesonide/formoterol fumarate dihydrate
budezonid/formoterolijev fumarat dihidrat
Budesonide/Formoterol Furmarate Dihydrate 160/4.5 µg bd + as needed
budezonid/formoterolijev fumarat dihidrat 160/4,5 µg
Budesonide/Formoterol Furmarate Dihydrate 160/4.5 µg bd + as needed
budezonid/formoterolijev fumarat dihidrat 320/9 µg 2-krat
Budesonide/Formoterol Furmarate Dihydrate 320/9 µg bd + terbutaline 0.4 mg as needed
na dan + terbutalin 0,4 mg po potrebi
Budesonide/formoterol maintenance therapy
Vzdrževalno zdravljenje astme z budezonidom/formoterolom
Budesonide/Formoterol Teva 160 mcg/4.5 mcg inhalation powder
Budezonid/formoterol Teva 160 mcg/4,5 mcg prašek za inhaliranje
Budesonide/Formoterol Teva 160 micrograms /4.5 micrograms inhalation powder
Budezonid/formoterol Teva 160 mikrogramov/4,5 mikrogramov prašek za inhaliranje
Budesonide/Formoterol Teva 160 micrograms/4.5 micrograms, inhalation powder
Budezonid/formoterol Teva 160 mikrogramov/4,5 mikrogramov, prašek za inhaliranje
Budesonide/Formoterol Teva 320 mcg/9 mcg inhalation powder
Budezonid/formoterol Teva 320 mcg/9 mcg prašek za inhaliranje
Budesonide/Formoterol Teva 320 micrograms/9 micrograms, inhalation powder
Budezonid/formoterol Teva 320 mikrogramov/9 mikrogramov, prašek za inhaliranje
Budesonide/Formoterol Teva can also be used to treat the symptoms of severe COPD in adults.
Zdravilo Budezonid/formoterol Teva se lahko uporablja tudi za zdravljenje simptomov hude KOPB pri odraslih.
Budesonide/Formoterol Teva contains formoterol and budesonide, which have different modes of action and show additive effects in terms of reduction of asthma exacerbations.
Zdravilo Budezonid/formoterol Teva vsebuje zdravilni učinkovini formoterol in budezonid, ki imata različna mehanizma delovanja, njuni učinki pri zmanjšanju pogostnosti poslabšanj astme pa so aditivni.
Budesonide/Formoterol Teva is a ‘hybrid medicine’.
Zdravilo Budesonide/Formoterol Teva je „hibridno zdravilo“.
Budesonide/Formoterol Teva is also used to relieve the symptoms of severe chronic obstructive pulmonary disease (COPD) in adults who have had exacerbations (flare–ups) of the disease in the past despite regular treatment.
Zdravilo Budesonide/Formoterol Teva se uporablja tudi za zdravljenje simptomov hude kronične obstruktivne pljučne bolezni (KOPB) pri odraslih s ponavljajočimi se poslabšanji simptomov bolezni v preteklosti kljub rednemu zdravljenju.
Budesonide/Formoterol Teva is indicated in adults 18 years of age and older only.
Zdravilo Budezonid/formoterol Teva je indicirano izklučno pri odraslih, starih 18 let in več.
Budesonide/Formoterol Teva is not an appropriate treatment for the adult patient with only mild asthma who is not adequately controlled with an inhaled corticosteroid and “as needed” inhaled short-acting β2 adrenoreceptor agonists.
Zdravljenje z zdravilom Budezonid/formoterol Teva ni ustrezno pri odraslih bolnikih z blago obliko astme, ki ni ustrezno nadzorovana z inhalacijskim kortikosteroidi in inhalacijskimi kratkodelujočimi agonisti adrenergičnih receptorjev β2, ki se uporabljajo po potrebi.
Budesonide/Formoterol Teva is NOT indicated for use in children 12 years of age and younger or adolescents 13 to 17 years of age.
Zdravilo Budezonid/formoterol Teva NI namenjeno za uporabo pri otrocih, starih 12 let in manj, ali mladostnikih, starih od 13 let do 17 let.
Budesonide/Formoterol Teva is NOT indicated for use in children, 12 years of age and younger or adolescents, 13 to 17 years of age.
Zdravilo Budezonid/formoterol Teva NI namenjeno za uporabo pri otrocih, starih 12 let in manj, ali mladostnikih, starih od 13 do 17 let.
Budesonide/Formoterol Teva Pharma B.V.
Budezonid/formoterol Teva Pharma B.V
Budesonide/Formoterol Teva Pharma B.V. 160 mcg/4.5 mcg inhalation powder
Budezonid/formoterol Teva Pharma B.V. 160 mcg/4,5 mcg prašek za inhaliranje
Budesonide/Formoterol Teva Pharma B.V. 160 micrograms / 4.5 micrograms inhalation powder
Budezonid/formoterol Teva Pharma B.V. 160 mikrogramov/4,5 mikrogramov prašek za inhaliranje
Budesonide/Formoterol Teva Pharma B.V. 160 micrograms / 4.5 micrograms inhalation powder.
Budezonid/formoterol Teva Pharma B.V. 160 mikrogramov/4,5 mikrogramov prašek za inhaliranje
Budesonide/Formoterol Teva Pharma B.V. 160 micrograms /4.5 micrograms inhalation powder
Budezonid/formoterol Teva Pharma B.V. 160 mikrogramov/4,5 mikrogramov prašek za inhaliranje
Budesonide/Formoterol Teva Pharma B.V. 160 micrograms/4.5 micrograms, inhalation powder
Budezonid/formoterol Teva Pharma B.V. 160 mikrogramov/4,5 mikrogramov, prašek za inhaliranje
Budesonide/Formoterol Teva Pharma B.V. 320 micrograms/9 micrograms inhalation powder
Budezonid/formoterol Teva Pharma B.V. 320 mikrogramov/9 mikrogramov prašek za inhaliranje
Budesonide/Formoterol Teva Pharma B.V. 320 micrograms/9 micrograms inhalation powder.
Budezonid/formoterol Teva Pharma B.V. 320 mikrogramov/9 mikrogramov prašek za inhaliranje
Budesonide/Formoterol Teva Pharma B.V. can be used for the regular treatment of asthma.
Zdravilo Budesonide/Formoterol Teva Pharma B.V. se lahko uporablja za redno zdravljenje astme.
Budesonide/Formoterol Teva Pharma B.V. contains formoterol and budesonide, which have different modes of action and show additive effects in terms of reduction of asthma exacerbations.
Zdravilo Budezonid/formoterol Teva Pharma B.V. vsebuje učinkovini formoterol in budezonid, ki imata različna mehanizma delovanja, njuni učinki pri zmanjšanju pogostnosti poslabšanj astme pa so aditivni.
Budesonide/Formoterol Teva Pharma B.V. contains formoterol and budesonide, which have different modes of action and show additive effects in terms of reduction of asthma exacerbations.
Zdravilo Budezonid/formoterol Teva Pharma B.V. vsebuje zdravilni učinkovini formoterol in budezonid, ki imata različna mehanizma delovanja, njuni učinki pri zmanjšanju pogostnosti poslabšanj astme pa so aditivni.
Budesonide/Formoterol Teva Pharma B.V. contains lactose
Zdravilo Budezonid/formoterol Teva Pharma B.V. vsebuje laktozo.
Budesonide/Formoterol Teva Pharma B.V. contains two different active substances: budesonide and formoterol fumarate dihydrate.
Zdravilo Budezonid/formoterol Teva Pharma B.V. vsebuje dve različni zdravilni učinkovini: budezonid in formoterolijev fumarat dihidrat.
Budesonide/Formoterol Teva Pharma B.V. has no or negligible influence on the ability to drive and use machines.
Zdravilo Budezonid/formoterol Teva Pharma B.V. nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Budesonide/Formoterol Teva Pharma B.V. is a medicine that contains the active substances budesonide and formoterol.
Budesonide/Formoterol Teva Pharma B.V. je zdravilo, ki vsebuje zdravilni učinkovini budezonid in formoterol.
Budesonide/Formoterol Teva Pharma B.V. is a ‘hybrid medicine’.
Zdravilo Budesonide/Formoterol Teva Pharma B.V. je „hibridno zdravilo“.
Budesonide/Formoterol Teva Pharma B.V. is an inhalation powder.
Zdravilo Budezonid/formoterol Teva Pharma B.V. je prašek za inhaliranje.
Budesonide/Formoterol Teva Pharma B.V. is indicated for use in adults 18 years of age and older only.
Zdravilo Budezonid/formoterol Teva Pharma B.V. je namenjeno izključno za uporabo pri odraslih osebah, starih 18 let in več.
Budesonide/Formoterol Teva Pharma B.V. is indicated in adults 18 years of age and older only.
Zdravilo Budezonid/formoterol Teva Pharma B.V. je indicirano izključno pri odraslih, starih 18 let in več.
Budesonide/Formoterol Teva Pharma B.V. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate:
Zdravilo Budezonid/formoterol Teva Pharma B.V. je indicirano za redno zdravljenje astme v primerih, ko je primerna kombinacija zdravil (inhalacijski kortikosteroid in dolgodelujoči agonist adrenergičnih receptorjev β2):
Budesonide/Formoterol Teva Pharma B.V. is not an appropriate treatment for the adult patient with only mild asthma who is not adequately controlled with an inhaled corticosteroid and “as needed” inhaled short- acting β2 adrenoreceptor agonists.
Zdravljenje z zdravilom Budezonid/formoterol Teva Pharma B.V. ni ustrezno pri odraslih bolnikih z blago obliko astme, ki ni ustrezno nadzorovana z inhalacijskim kortikosteroidi in inhalacijskimi kratkodelujočimi agonisti adrenoreceptorjev β2, ki se uporabljajo po potrebi.
Budesonide/Formoterol Teva Pharma B.V. is NOT indicated for use in children 12 years of age and younger or adolescents 13 to 17 years of age.
Zdravilo Budezonid/formoterol Teva Pharma B.V. NI namenjeno za uporabo pri otrocih, starih 12 let in manj, ali mladostnikih, starih od 13 let do 17 let.
Budesonide/Formoterol Teva Pharma B.V. is not indicated for use in children, 12 years of age and younger or adolescents, 13 to 17 years of age.
Zdravilo Budezonid/formoterol Teva Pharma B.V. ni indicirano za uporabo pri otrocih, starih 12 let ali manj, ali mladostnikih, starih od 13 do 17 let.
Budesonide/Formoterol Teva Pharma B.V. is NOT indicated for use in children, 12 years of age and younger or adolescents, 13 to 17 years of age.
Zdravilo Budezonid/formoterol Teva Pharma B.V. NI namenjeno za uporabo pri otrocih, starih 12 let in manj, ali mladostnikih, starih od 13 do 17 let.
Budesonide/Formoterol Teva Pharma B.V. is not indicated in children and adolescents under the age of 18 years (see section 4.2).
Zdravilo Budezonid/formoterol Teva Pharma B.V. ni indicirano pri otrocih in mladostnikih, mlajših od 18 let (glejte poglavje 4.2).
Budesonide/Formoterol Teva Pharma B.V. is not intended for the initial management of asthma.
Zdravilo Budezonid/formoterol Teva Pharma B.V. ni primerno za začetno zdravljenje astme.